IS7725A - Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra - Google Patents

Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra

Info

Publication number: IS7725A
Authority: IS; Iceland
Prior art keywords: imidazolopyridine; manufacture; methods
Prior art date: 2002-09-06

Application number

IS7725A

Other languages

English (en)

Inventor

Lee Wen-Cherng

Sun Lihong

Boriack-Sjodin Paula

Beth Carter Mary

Chuaqui Claudio

S Choi Michael

Singh Juswinder

Original Assignee

Biogen Idec Ma, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-06

Filing date

2005-03-04

Publication date

2005-03-04

2003-09-05 Priority claimed from PCT/US2003/027721 external-priority patent/WO2004021989A2/en

2005-03-04 Application filed by Biogen Idec Ma, Inc. filed Critical Biogen Idec Ma, Inc.

2005-03-04 Publication of IS7725A publication Critical patent/IS7725A/is

Links

GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Cardiology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Obesity (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS7725A 2002-09-06 2005-03-04 Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra IS7725A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40881102P	2002-09-06	2002-09-06
PCT/US2003/027721 WO2004021989A2 (en)	2002-09-06	2003-09-05	Imidazolopyridines and methods of making and using the same

Publications (1)

Publication Number	Publication Date
IS7725A true IS7725A (is)	2005-03-04

Family

ID=31978684

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IS7726A IS7726A (is)	2002-09-06	2005-03-04	Pyrazólólpyridín og aðferðir til þess að búa þau til og nota
IS7725A IS7725A (is)	2002-09-06	2005-03-04	Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IS7726A IS7726A (is)	2002-09-06	2005-03-04	Pyrazólólpyridín og aðferðir til þess að búa þau til og nota

Country Status (20)

Country	Link
US (1)	US7691865B2 (is)
EP (1)	EP1551398A4 (is)
JP (1)	JP2006502165A (is)
KR (1)	KR20050057235A (is)
CN (1)	CN1694698A (is)
AR (1)	AR041207A1 (is)
AU (1)	AU2003268447B2 (is)
BR (1)	BR0314053A (is)
CA (1)	CA2497970A1 (is)
EA (1)	EA009441B1 (is)
GE (1)	GEP20074125B (is)
IS (2)	IS7726A (is)
MX (1)	MXPA05002443A (is)
NO (1)	NO20051503D0 (is)
NZ (1)	NZ539069A (is)
PL (1)	PL375699A1 (is)
RS (1)	RS20050200A (is)
UA (1)	UA80295C2 (is)
WO (1)	WO2004022054A1 (is)
ZA (1)	ZA200501856B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
JP4931589B2 (ja) *	2004-07-02	2012-05-16	正明松岡	ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
AU2005295734A1 (en) *	2004-10-15	2006-04-27	Biogen Idec Ma Inc.	Methods of treating vascular injuries
US20070155738A1 (en)	2005-05-20	2007-07-05	Alantos Pharmaceuticals, Inc.	Heterobicyclic metalloprotease inhibitors
EP1928237A4 (en)	2005-09-02	2011-03-09	Abbott Lab	NEW HETEROCYCLES BASED ON IMIDAZO
EP1873157A1 (en) *	2006-06-21	2008-01-02	Bayer Schering Pharma Aktiengesellschaft	Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CN101553254A (zh)	2006-10-03	2009-10-07	建新公司	TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
JP2010540451A (ja) *	2007-09-20	2010-12-24	ワイス・エルエルシー	ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法
CN103463084A (zh) *	2008-03-14	2013-12-25	大塚制药株式会社	制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN101544634B (zh) *	2008-03-27	2011-08-10	天津药物研究院	2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途
EP2402335A1 (en) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
EP2402344A1 (en) *	2010-06-29	2012-01-04	Basf Se	Pyrazole fused bicyclic compounds
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
US9468612B2 (en)	2011-10-26	2016-10-18	Seattle Children's Hospital	Cysteamine in the treatment of fibrotic disease
PT2970205T (pt)	2013-03-14	2019-08-26	Tolero Pharmaceuticals Inc	Inibidores da jak2 e da alk2 e métodos para a sua utilização
ES3069593T3 (en)	2013-08-23	2026-06-09	Neupharma Inc	Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
JP2017501145A (ja)	2013-12-23	2017-01-12	ノージンビーブイ	Ｃｃｒ９調節因子として有用な化合物
US10342795B2 (en) *	2014-03-27	2019-07-09	Janssen Pharmaceutica Nv	Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
CN109843858B (zh) *	2016-08-15	2023-05-05	润新生物公司	某些化学实体、组合物及方法
KR20210038906A (ko)	2018-07-26	2021-04-08	스미토모 다이니폰 파마 온콜로지, 인크.	비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
ES3065954T3 (en) *	2019-05-13	2026-05-08	Relay Therapeutics Inc	Fgfr inhibitors and methods of use thereof
CN115052663B (zh)	2020-01-08	2026-06-09	辛瑟斯治疗股份有限公司	Alk5抑制剂缀合物及其用途
CN112707902B (zh) *	2020-03-23	2022-04-15	杭州阿诺生物医药科技有限公司	TGF-β受体抑制剂
CN114380818B (zh) *	2020-10-16	2026-04-10	四川科伦博泰生物医药股份有限公司	吡唑并吡啶类化合物，及其药物组合物、制备方法和用途
WO2024258967A1 (en)	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anti-cd5 antibodies and their uses

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3940486A (en)	1971-05-10	1976-02-24	Ciba-Geigy Corporation	Imidazole derivatives in the treatment of pain
US4302464A (en)	1980-10-16	1981-11-24	Pfizer Inc.	Imidazolylpyridine therapeutic agents
US4686231A (en)	1985-12-12	1987-08-11	Smithkline Beckman Corporation	Inhibition of 5-lipoxygenase products
JP2753659B2 (ja) *	1990-09-03	1998-05-20	株式会社大塚製薬工場	ピラゾール誘導体
US5916891A (en)	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
US5656644A (en)	1994-07-20	1997-08-12	Smithkline Beecham Corporation	Pyridyl imidazoles
IL104369A0 (en)	1992-01-13	1993-05-13	Smithkline Beecham Corp	Novel compounds and compositions
US5593991A (en)	1993-07-16	1997-01-14	Adams; Jerry L.	Imidazole compounds, use and process of making
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
US5670527A (en)	1993-07-16	1997-09-23	Smithkline Beecham Corporation	Pyridyl imidazole compounds and compositions
US5559137A (en)	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
GB9423460D0 (en)	1994-11-21	1995-01-11	Merck Sharp & Dohme	Therapeutic agents
US5514505A (en)	1995-05-15	1996-05-07	Xerox Corporation	Method for obtaining improved image contrast in migration imaging members
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en)	1995-06-07	2002-04-09	Smithkline Beecham Corporation	Amino substituted pyrimidine containing compounds
US5854276A (en)	1995-06-29	1998-12-29	Fujisawa Pharmaceutical Co., Ltd.	Substance WF16616, process for production thereof, and use thereof
US5837719A (en)	1995-08-10	1998-11-17	Merck & Co., Inc.	2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en)	1995-08-10	1998-08-11	Merck & Co., Inc.	2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6083949A (en)	1995-10-06	2000-07-04	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en)	1995-10-13	1997-04-30	Merck & Co Inc	Treatment of Raf-mediated cancers with imidazole derivatives
GB9525296D0 (en) *	1995-12-11	1996-02-07	Merck Sharp & Dohme	Therapeutic agents
ZA9610687B (en)	1995-12-22	1997-09-29	Smithkline Beecham Corp	Novel synthesis.
US6046208A (en)	1996-01-11	2000-04-04	Smithkline Beecham Corporation	Substituted imidazole compounds
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US5756499A (en)	1996-01-11	1998-05-26	Smithkline Beecham Corporation	Substituted imidazole compounds
WO1997028160A1 (en)	1996-02-01	1997-08-07	Smithkline Beecham Corporation	Endothelin receptor antagonists
EP1005343A4 (en)	1996-03-08	2000-06-07	Smithkline Beecham Corp	USE OF CSAIDS AS ANGIOGENESIS INHIBITORS
US6096748A (en)	1996-03-13	2000-08-01	Smithkline Beecham Corporation	Pyrimidine compounds useful in treating cytokine mediated diseases
WO1997035855A1 (en)	1996-03-25	1997-10-02	Smithkline Beecham Corporation	Novel treatment for cns injuries
WO1997035856A1 (en)	1996-03-25	1997-10-02	Smithkline Beecham Corporation	Novel treatment for cns injuries
US5883105A (en)	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5854265A (en)	1996-04-03	1998-12-29	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en)	1996-04-03	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6080870A (en)	1996-04-03	2000-06-27	Merck & Co., Inc.	Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5880140A (en)	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en)	1996-04-03	1999-02-16	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
AU708883B2 (en)	1996-06-10	1999-08-12	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
US5854264A (en)	1996-07-24	1998-12-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
HUP9903330A2 (hu)	1996-11-19	2000-03-28	Amgen Inc.	Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
US6410729B1 (en)	1996-12-05	2002-06-25	Amgen Inc.	Substituted pyrimidine compounds and methods of use
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
US5939439A (en)	1996-12-30	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
HUP0002842A3 (en)	1997-04-24	2002-01-28	Ortho Mcneil Pharm Inc	Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
US6087381A (en)	1997-05-22	2000-07-11	G. D. Searle & Company	Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
US5932576A (en)	1997-05-22	1999-08-03	G. D. Searle & Company	3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
AU742293B2 (en)	1997-06-12	2001-12-20	Aventis Pharma Limited	Imidazolyl-cyclic acetals
US20020156104A1 (en)	1997-06-13	2002-10-24	Jerry L. Adams	Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
AU8757098A (en)	1997-06-30	1999-02-10	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
US7301021B2 (en)	1997-07-02	2007-11-27	Smithkline Beecham Corporation	Substituted imidazole compounds
US6562832B1 (en)	1997-07-02	2003-05-13	Smithkline Beecham Corporation	Substituted imidazole compounds
TW517055B (en)	1997-07-02	2003-01-11	Smithkline Beecham Corp	Novel substituted imidazole compounds
JP2001526230A (ja)	1997-12-19	2001-12-18	スミスクライン・ビーチャム・コーポレイション	ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
ES2221426T3 (es)	1998-08-20	2004-12-16	Smithkline Beecham Corporation	Nuevos compuestos de triazol sustituidos.
US6548503B1 (en)	1998-11-04	2003-04-15	Smithkline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en)	1998-12-16	2001-05-29	Smithkline Beecham Corporation	Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en)	1998-12-21	2001-09-11	Michael Zawada	Use of kinase inhibitors for treating neurodegenerative diseases
KR100711538B1 (ko)	1998-12-25	2007-04-27	아스카 세이야쿠 가부시키가이샤	아미노피라졸 유도체
CA2368630A1 (en)	1999-04-02	2000-10-12	Ruth R. Wexler	Aryl sulfonyls as factor xa inhibitors
AU4798000A (en)	1999-04-09	2000-11-14	Smithkline Beecham Corporation	Triarylimidazoles
CO5170501A1 (es)	1999-04-14	2002-06-27	Novartis Ag	AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
CN1281604C (zh)	1999-06-03	2006-10-25	帝国脏器制药株式会社	取代吡唑化合物
DE60027431T2 (de)	1999-07-02	2007-07-12	Stuart A. Rancho Santa Fe Lipton	Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
US20030109428A1 (en)	1999-12-01	2003-06-12	John Bertin	Novel molecules of the card-related protein family and uses thereof
US6610688B2 (en)	1999-12-21	2003-08-26	Sugen, Inc.	4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
AR029803A1 (es)	2000-02-21	2003-07-16	Smithkline Beecham Plc	Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1263753B1 (en)	2000-03-06	2004-05-06	SmithKline Beecham plc	Imidazol derivatives as raf kinase inhibitors
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
JP4722318B2 (ja) *	2000-06-05	2011-07-13	ローム株式会社	チップ抵抗器
GB0011092D0 (en)	2000-05-08	2000-06-28	Black James Foundation	Gastrin and cholecystokinin receptor ligands (III)
EP1289523A1 (en)	2000-06-01	2003-03-12	Merck & Co., Inc.	Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
AU2001268711A1 (en)	2000-06-23	2002-01-08	Bristol-Myers Squibb Pharma Company	Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en)	2000-09-05	2000-10-18	Astrazeneca Ab	Chemical compounds
AU2001290912A1 (en)	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002024680A1 (en)	2000-09-21	2002-03-28	Smithkline Beecham P.L.C.	Imidazole derivatives as raf kinase inhibitors
JP2004511554A (ja)	2000-10-18	2004-04-15	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	炎症性疾患の治療で有用な置換イミダゾール
US6630325B1 (en)	2000-10-19	2003-10-07	Maine Medical Center Research Institute	Compositions, methods and kits relating to remodel
US6603005B2 (en)	2000-11-15	2003-08-05	Aventis Pharma S.A.	Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
EP1349851A4 (en)	2000-11-16	2004-09-08	Smithkline Beecham Corp	COMPOUNDS
GB0027987D0 (en)	2000-11-16	2001-01-03	Smithkline Beecham Plc	Compounds
ES2289004T3 (es)	2000-11-20	2008-02-01	Smithkline Beecham Corporation	Nuevos compuestos.
AU2002226674B2 (en) *	2000-12-28	2007-03-22	Ono Pharmaceutical Co., Ltd.	Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
ATE291020T1 (de)	2001-02-02	2005-04-15	Smithkline Beecham Corp	Pyrazolderivate gegen tgf überexprimierung
GB0102672D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102665D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102668D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
WO2002062787A1 (en) *	2001-02-02	2002-08-15	Glaxo Group Limited	Pyrazoles as tgf inhibitors
JP2004532234A (ja)	2001-04-27	2004-10-21	バーテックス　ファーマシューティカルズ　インコーポレイテッド	トリアゾール由来キナーゼインヒビターおよびその使用
US6727364B2 (en)	2001-04-30	2004-04-27	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en)	2001-04-30	2004-09-07	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
IL159811A0 (en)	2001-07-13	2004-06-20	Neurogen Corp	Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
GB0127433D0 (en)	2001-11-15	2002-01-09	Smithkline Beecham Corp	Compounds
WO2003050120A1 (en)	2001-12-11	2003-06-19	Smithkline Beecham Corporation	Pyrazolo-pyridine derivatives as antiherpes agents
AU2003229305A1 (en)	2002-05-17	2003-12-02	Scios, Inc.	TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
WO2004026871A1 (en) *	2002-09-17	2004-04-01	Eli Lilly And Company	Novel pyrazolopyridine derivatves as pharmaceutical agents
CN1681805A (zh)	2002-09-18	2005-10-12	辉瑞产品公司	作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
MXPA05002332A (es)	2002-09-18	2005-06-08	Pfizer Prod Inc	Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
AU2003300099A1 (en)	2003-01-02	2004-07-29	Millennium Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
PA8595001A1 (es)	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7973169B2 (en)	2003-09-06	2011-07-05	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters

2003
- 2003-05-09 UA UAA200503095A patent/UA80295C2/uk unknown
- 2003-09-05 WO PCT/US2003/027722 patent/WO2004022054A1/en not_active Ceased
- 2003-09-05 BR BR0314053-9A patent/BR0314053A/pt not_active IP Right Cessation
- 2003-09-05 PL PL03375699A patent/PL375699A1/xx not_active Application Discontinuation
- 2003-09-05 AU AU2003268447A patent/AU2003268447B2/en not_active Ceased
- 2003-09-05 CA CA002497970A patent/CA2497970A1/en not_active Abandoned
- 2003-09-05 EP EP03749412A patent/EP1551398A4/en not_active Withdrawn
- 2003-09-05 RS YUP-2005/0200A patent/RS20050200A/sr unknown
- 2003-09-05 JP JP2004534571A patent/JP2006502165A/ja active Pending
- 2003-09-05 GE GEAP20038727A patent/GEP20074125B/en unknown
- 2003-09-05 MX MXPA05002443A patent/MXPA05002443A/es active IP Right Grant
- 2003-09-05 EA EA200500450A patent/EA009441B1/ru not_active IP Right Cessation
- 2003-09-05 KR KR1020057003874A patent/KR20050057235A/ko not_active Withdrawn
- 2003-09-05 CN CNA038248670A patent/CN1694698A/zh active Pending
- 2003-09-05 NZ NZ539069A patent/NZ539069A/en unknown
- 2003-09-05 US US10/526,839 patent/US7691865B2/en not_active Expired - Fee Related
- 2003-09-08 AR ARP030103250A patent/AR041207A1/es unknown
2005
- 2005-03-03 ZA ZA200501856A patent/ZA200501856B/en unknown
- 2005-03-04 IS IS7726A patent/IS7726A/is unknown
- 2005-03-04 IS IS7725A patent/IS7725A/is unknown
- 2005-03-21 NO NO20051503A patent/NO20051503D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IS7726A (is)	2005-03-04
ZA200501856B (en)	2006-04-26
PL375699A1 (en)	2005-12-12
JP2006502165A (ja)	2006-01-19
WO2004022054A1 (en)	2004-03-18
NO20051503L (no)	2005-03-21
EP1551398A1 (en)	2005-07-13
UA80295C2 (en)	2007-09-10
AR041207A1 (es)	2005-05-11
EA200500450A1 (ru)	2005-08-25
US20060106033A1 (en)	2006-05-18
MXPA05002443A (es)	2005-09-30
AU2003268447B2 (en)	2008-07-24
EP1551398A4 (en)	2006-06-07
US7691865B2 (en)	2010-04-06
GEP20074125B (en)	2007-06-11
BR0314053A (pt)	2005-07-19
NO20051503D0 (no)	2005-03-21
CN1694698A (zh)	2005-11-09
CA2497970A1 (en)	2004-03-18
NZ539069A (en)	2007-03-30
EA009441B1 (ru)	2007-12-28
AU2003268447A1 (en)	2004-03-29
KR20050057235A (ko)	2005-06-16
RS20050200A (sr)	2007-08-03

Publication	Publication Date	Title
IS8305A (is)	2006-02-16	Bindandi smíðar og aðferðir við notkun þeirra
IS7977A (is)	2005-08-12	Samsetningar og aðferð til samsettra meðferðar
DK1539224T3 (da)	2008-03-31	Antimikrobielt præparat og fremgangsmåde til anvendelse
NO2017017I1 (no)	2017-05-04	umeklinidium og vilanterol
DK1367501T3 (da)	2012-07-16	Leksikon med inddelte data og fremgangsmåde til anvendelse deraf
ATE410421T1 (de)	2008-10-15	P38 inhibitor und anwendungsverfahren dafür
DK1513873T3 (da)	2014-11-03	Terapeutiske epitoper og anvendelser deraf
IS7966A (is)	2005-07-29	Pyrazól og aðferðir við að búa þau til og notkun þeirra
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1711207T3 (da)	2013-03-11	Interferon-alpha-antistoffer og anvendelse heraf
DK3246399T3 (da)	2021-10-04	Alfavirus-partikler og fremgangsmåder til fremstilling
NO20054453D0 (no)	2005-09-26	P38 inhibitorer og fremgangsmater for anvendelse derav
NO20033387D0 (no)	2003-07-29	Modifiserte antistoffer og fremgangsmåter for anvendelse
IS7907A (is)	2005-06-22	Astmi og stillar ofnæmisbólgu
NO20044148L (no)	2004-09-30	Sammensetning og fremgangsmate for bronnrensing
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
NO20033854L (no)	2003-10-28	N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20043907L (no)	2004-09-17	Partielle og fullstendige agonister av A1-adenosinreseptorer
PT1558595E (pt)	2010-01-15	Piperazinil e diazepanil benzamidas e benzotioamidas
DK1601744T3 (da)	2012-08-20	Forgasningsapparat og fremgangsmåde
IS2482B (is)	2008-12-15	Arómatísk súlfón og læknisfræðileg notkun þeirra
DK1589938T3 (da)	2011-03-14	Mundplejesammensætninger og fremgangsmåder hertil
NO20053874L (no)	2005-10-19	Formulering og metoder for behandling av thrombocytemi
DE60238174D1 (de)	2010-12-16	Fluoropolymere und Herstellungs- und Verwendungsverfahren
NO20044106L (no)	2004-10-27	Omkonstruerte baculoviruser og anvendelse derav